Reply to: “Are FIB-4 and liver stiffness measurement interchangeable for HCC risk stratification in MASLD?”

作者：Georg Semmler, Jan Embacher, Mattias Mandorfer · 发表于：JHEP Reports · 年份：2026 · DOI：10.1016/j.jhepr.2026.101933 · 研究领域：Liver Disease Diagnosis and Treatment、Liver Disease and Transplantation、Liver Diseases and Immunity